PT2854768T - Composições farmacêuticas de pemetrexed - Google Patents

Composições farmacêuticas de pemetrexed

Info

Publication number
PT2854768T
PT2854768T PT137300703T PT13730070T PT2854768T PT 2854768 T PT2854768 T PT 2854768T PT 137300703 T PT137300703 T PT 137300703T PT 13730070 T PT13730070 T PT 13730070T PT 2854768 T PT2854768 T PT 2854768T
Authority
PT
Portugal
Prior art keywords
pemetrexed
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
PT137300703T
Other languages
English (en)
Inventor
Khattar Dhiraj
Khanna Rajesh
Yadav Mukti
Burman Krishanu
Original Assignee
Fresenius Kabi Oncology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2854768(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fresenius Kabi Oncology Ltd filed Critical Fresenius Kabi Oncology Ltd
Publication of PT2854768T publication Critical patent/PT2854768T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
PT137300703T 2012-05-30 2013-05-30 Composições farmacêuticas de pemetrexed PT2854768T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1648DE2012 2012-05-30

Publications (1)

Publication Number Publication Date
PT2854768T true PT2854768T (pt) 2017-05-19

Family

ID=48656253

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137300703T PT2854768T (pt) 2012-05-30 2013-05-30 Composições farmacêuticas de pemetrexed

Country Status (8)

Country Link
US (2) US9421207B2 (pt)
EP (2) EP2854768B1 (pt)
DK (1) DK2854768T3 (pt)
ES (1) ES2624442T3 (pt)
LT (1) LT2854768T (pt)
PT (1) PT2854768T (pt)
SI (1) SI2854768T1 (pt)
WO (1) WO2013179248A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014167585A1 (en) * 2013-04-12 2014-10-16 Actavis Group Ptc Ehf. Pemetrexed formulation
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
WO2014198337A1 (en) * 2013-06-14 2014-12-18 Synthon B.V. Stable and water soluble pharmaceutical compositions comprising pemetrexed
JP2016527227A (ja) * 2013-07-16 2016-09-08 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドトロメタミン塩の新規な結晶形
CN105611932B (zh) 2013-10-03 2019-02-12 富士胶片株式会社 注射液制剂及其制造方法
JP6120766B2 (ja) * 2013-12-27 2017-04-26 富士フイルム株式会社 注射液製剤及びその製造方法
PL3124026T3 (pl) * 2014-03-28 2019-03-29 Fujifilm Corporation Preparat iniekcyjny i sposób jego wytwarzania
GB201418555D0 (en) * 2014-10-16 2014-12-03 Teva Gmbh Pemetrexed formulations
PL3206666T3 (pl) * 2014-10-16 2020-09-21 Synthon B.V. Ciekła kompozycja farmaceutyczna zawierająca pemetreksed
JP6869899B2 (ja) * 2015-02-13 2021-05-12 サン・ファーマシューティカル・インダストリーズ・リミテッド 静脈内注入剤形
KR101919436B1 (ko) * 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법
GB201511246D0 (en) * 2015-06-25 2015-08-12 Actavis Group Ptc Ehf Pharmaceutical formulation
KR101693675B1 (ko) * 2015-12-14 2017-01-06 주식회사 종근당 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
US20170239250A1 (en) 2016-02-19 2017-08-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
AU2016393213B2 (en) * 2016-02-19 2022-03-31 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
US20200246263A1 (en) * 2017-08-29 2020-08-06 Fresenius Kabi Oncology Limited Stable liquid compositions of pemetrexed
PL3470045T3 (pl) 2017-10-10 2021-03-08 Sun Pharmaceutical Industries Ltd Dożylna infuzyjna postać dawkowania dla pemetreksedu
CN108158989B (zh) * 2018-03-01 2020-08-28 河北爱尔海泰制药有限公司 一种盐酸氨溴索注射液组合物
US10966982B2 (en) * 2018-11-20 2021-04-06 Cipla Limited Stable pharmaceutical formulations of pemetrexed
WO2020222151A1 (en) * 2019-05-01 2020-11-05 Intas Pharmaceuticals Ltd. A stable, ready to use aqueous pharmaceutical composition of pemetrexed
WO2021192472A1 (ja) * 2020-03-24 2021-09-30 ナガセ医薬品株式会社 ペメトレキセド製剤
JP7282065B2 (ja) * 2020-10-05 2023-05-26 イーグル ファーマシューティカルズ, インコーポレイテッド ペメトレキセド製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02502534A (ja) 1987-12-18 1990-08-16 チバ‐ガイギー アクチェンゲゼルシャフト 1‐メチル‐β‐オキソ‐α‐(フェニルカルバモイル)‐2‐ピロールプロピオニトリルのトロメタミン塩
IL96531A (en) 1989-12-11 1995-08-31 Univ Princeton History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them)
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US6686365B2 (en) 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
WO2002002093A2 (en) 2000-06-30 2002-01-10 Eli Lilly And Company Combination containing an antifolate and methylmalonic acid lowering agent
CN100364993C (zh) 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
EP1818049A3 (en) 2006-02-10 2008-11-19 LifeCycle Pharma A/S Stabilized Atorvastatin
CN101081301A (zh) 2006-05-29 2007-12-05 海南天源康泽医药科技有限公司 含有培美曲塞的药物组合物
US8629152B2 (en) 2006-08-14 2014-01-14 Sicor, Inc. Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
WO2010030598A2 (en) 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
IT1401207B1 (it) 2010-06-30 2013-07-12 Magic Production Group S A Dispositivo e procedimento per la chiusura di contenitori
WO2012015810A2 (en) 2010-07-28 2012-02-02 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
WO2014167585A1 (en) 2013-04-12 2014-10-16 Actavis Group Ptc Ehf. Pemetrexed formulation

Also Published As

Publication number Publication date
US9421207B2 (en) 2016-08-23
EP3210629A1 (en) 2017-08-30
US20150111905A1 (en) 2015-04-23
DK2854768T3 (en) 2017-06-12
WO2013179248A1 (en) 2013-12-05
ES2624442T3 (es) 2017-07-14
US20160310495A1 (en) 2016-10-27
SI2854768T1 (sl) 2017-08-31
US9968608B2 (en) 2018-05-15
LT2854768T (lt) 2017-06-12
EP2854768B1 (en) 2017-03-22
EP2854768A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
ZA201703992B (en) Inhalable pharmaceutical compositions
SI2854768T1 (sl) Farmacevtski sestavki pemetrekseda
HK1209638A1 (en) Pharmaceutical compositions
GB201113662D0 (en) Pharmaceutical compositions
ZA201308208B (en) Pharmaceutical compositions
HK1199824A1 (en) Pharmaceutical compositions
ZA201501930B (en) Pharmaceutical composition
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
EP2917314A4 (en) OLIGOMERATZUSAMMENSETZUNG
IL266415A (en) Innovative pharmaceutical composition
IL237139A0 (en) Pharmaceutical compositions of memantine
PL2887924T3 (pl) Kompozycje farmaceutyczne etorykoksybu
GB201118181D0 (en) Pharmaceutical compositions
ZA201502987B (en) Pharmaceutical composition
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
GB201211153D0 (en) Pharmaceutical compositions
EP2884964A4 (en) PHARMACEUTICAL COMPOSITION OF PROPOFOL
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
EP2714715A4 (en) PHARMACEUTICAL COMPOSITIONS
IL238075A0 (en) pharmaceutical preparations
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
GB201204810D0 (en) Pharmaceutical compositions
ZA201400751B (en) Pharmaceutical composition